Evidence map›Paper›PMID 41436961›Full record

ArticleBMC cardiovascular disorders2025

Prevalence-incidence bias in longitudinal studies of rheumatic heart disease in Fiji.

Tuliana Cua, Shagorika Talukder, Mai Ling Perman, Daniel Engelman, Andrew Steer, Joseph Kado, Tom Parks

Abstract readComparative Study
In one paragraph

Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tuliana Cua *Rheumatic Heart Disease Prevention and Control Programme, Fiji Islands Ministry of Health and Medical Services, Suva, Fiji.
Shagorika Talukder *Department of Infectious Disease, Imperial College London, London, UK.
Mai Ling PermanDepartment of Internal Medicine, Fiji National University College of Medicine Nursing and Health Sciences, Suva, Fiji.
Daniel EngelmanInfection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Andrew SteerInfection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
Joseph KadoWesfarmers Centre for Vaccines and Infectious Diseases, The Kids Institute, Perth, Australia. joseph.kado@telethonkids.org.au.
Tom ParksDepartment of Infectious Disease, Imperial College London, London, UK. t.parks@imperial.ac.uk.

Funding

National Institute for Health and Care Research CL-2020-21-001Sir Halley Stewart Trust Research Grant 2013Wellcome TrustWellcome Trust 222098/Z/20/Z
6 · The paper itself

Abstract

backgroundRheumatic heart disease (RHD), a consequence of a dysregulated immune response to Streptococcus pyogenes infection, remains the most commonly acquired cardiovascular condition in under 25-year-olds. Predominantly occurring in low- and middle-income countries (LMICs), RHD has an estimated prevalence of 40.5 million cases globally, although RHD complication rates in endemic settings remain uncertain. Accordingly, we undertook a prospective cohort study of RHD mortality and morbidity in Fiji with the aim of comparing complication rates to those estimated in our previous retrospective studies based on routine data and record-linkage from this setting.

methodsWe prospectively ascertained RHD patients in the Central Division of Fiji from: (i) prevalent cases reviewed in echocardiography clinic prior to the study (May 2014-September 2015), and (ii) incident cases diagnosed in hospital (May 2014-October 2016). The primary endpoint comprised the earliest of RHD-attributable death, new onset heart failure or new onset stroke (assessed to October 2016). Differences between groups were assessed using a log-rank test (LRT). Additionally, to further investigate the issue of prevalence-incidence bias, rates of these events in the prospective cohort were also compared to those among patients with similar characteristics from our previously reported retrospective studies.

resultsDuring a median of 19.3 months follow-up, the primary endpoint occurred in six out of a total of 163 patients recruited to the study, with an incidence rate of 1.8 (95% CI, 0.6–5.5) and 5.3 (95% CI, 1.7–16.5) per 100 person-years in the prevalent and incident groups respectively (LRT, p = 0.13). Among 617 comparable individuals from our previous retrospective studies, the primary endpoint occurred in 24 patients with an incidence of 1.4 (95% CI, 0.7–2.5) and 6.4 (95% CI, 3.8–10.8) per 100 person-years in prevalent and incident groups respectively (LRT, p = 0.002).

conclusionsComplications of RHD were less frequent in the prevalent compared to incident groups, reaching statistical significance in the larger retrospective cohort. Reflecting the impact of systematic differences between the groups, these findings highlight the vulnerability of longitudinal studies of RHD to prevalence-incidence bias, underscoring the need for further robust and representative studies of RHD outcomes in LMICs to inform efforts to limit the impact of RHD globally.

Indexed as

Rheumatic Heart DiseaseAdultBiasFemaleFijiHeart FailureHumansIncidenceLongitudinal StudiesMaleMiddle AgedPrevalencePrognosisProspective StudiesRisk AssessmentRisk FactorsEpidemiologyPrevalence-incidence biasRheumatic heart diseaseValvular heart disease

Identifiers

PMID41436961
PMCPMC12837003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.